skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15307

Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells



Original Research

(12120) Total Article Views


Authors: Bao-An Chen, Pei-pei Mao, Jian Cheng, et al

Published Date June 2010 Volume 2010:5 Pages 437 - 444
DOI: http://dx.doi.org/10.2147/IJN.S10083

Bao-an Chen1, Pei-pei Mao1, Jian Cheng1, Feng Gao1, Guo-hua Xia1, Wen-lin Xu2, Hui-lin Shen2, Jia-hua Ding1, Chong Gao1, Qian Sun1, Wen-ji Chen1, Ning-na Chen1, Li-jie Liu3, Xiao-mao Li4, Xue-mei Wang5

1Department of Hematology, The Affiliated Zhongda Hospital, Clinical Medical School, Southeast University, Nanjing, People’s Republic of China; 2Department of Hematology, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, People’s Republic of China; 3Institution of Physiology, Southeast University, Nanjing, People’s Republic of China; 4Department of Physics, University of Saarland, Saarbruecken, Germany; 5State Key Lab of Bioelectronics (Chien-Shiung Wu Laboratory), Southeast University, Nanjing, People’s Republic of China

Abstract: In many instances, multidrug resistance (MDR) is mediated by increasing the expression at the cell surface of the MDR1 gene product, P-glycoprotein (P-gp), a 170-kD energy-dependent efflux pump. The aim of this study was to investigate the potential benefit of combination therapy with magnetic Fe3O4 nanoparticle [MNP (Fe3O4)] and MDR1 shRNA expression vector in K562/A02 cells. For stable reversal of “classical” MDR by short hairpin RNA (shRNA) aiming directly at the target sequence (3491–3509, 1539–1557, and 3103–3121 nucleotide) of MDR1 mRNA. PGC silencer-U6-neo-GFP-shRNA/MDR1 called PGY1–1, PGY1–2, and PGY1–3 were constructed and transfected into K562/A02 cells by lipofectamine 2000. After transfected and incubated with or without MNP (Fe3O4) for 48 hours, the transcription of MDR1 mRNA and the expression of P-gp were detected by quantitative real-time PCR and Western-blot assay respectively. Meanwhile intracellular concentration of DNR in K562/A02 cells was detected by flow cytometry (FCM). PGC silencer-U6-neo-GFP-shRNA/MDR1 was successfully constructed, which was confirmed by sequencing and PGY1–2 had the greatest MDR1 gene inhibitory ratio. Analysis of the reversal ratio of MDR, the concentration of daunorubicin (DNR) and the transcription of MDR1 gene and expression of P-gp in K562/A02 showed that combination of DNR with either MNP (Fe3O4) or PGY1–2 exerted a potent cytotoxic effect on K562/A02 cells, while combination of MNP (Fe3O4) and PGY1–2 could synergistically reverse multidrug resistance. Thus our in vitro data strongly suggested that a combination of MNP (Fe3O4) and shRNA expression vector might be a more sufficient and less toxic anti-MDR method on leukemia.

Keywords: K562/A02 cell line, multidrug resistance, magnetic nanoparticle of Fe3O4, recombinant plasmid vector PGY1–2




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Prof. Dr. Bao-An Chen

A promising strategy for overcoming MDR in tumor by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin
Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies
Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo
Daunorubicin-TiO2 nanocomposites as a “smart” pH-responsive drug delivery system
Effect of Fe3O4-magnetic nanoparticles on acute exercise enhanced KCNQ1 expression in mouse cardiac muscle
Effect of interaction of magnetic nanoparticles of Fe3O4 and artesunate on apoptosis of K562 cells
Effect of magnetic Fe3O4 nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells
Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells
Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line
Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells
Gambogic acid-loaded magnetic Fe3O4 nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1
Magnetic Fe3O4 nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells
Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance
Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice
Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe3O4 combined with cyclosporin A in murine models
Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice
Study of the enhanced anticancer efficacy of gambogic acid on Capan-1 pancreatic cancer cells when mediated via magnetic Fe3O4 nanoparticles
Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acid on phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells
Synergistic effect of magnetic nanoparticles of Fe3O4 with gambogic acid on apoptosis of K562 leukemia cells
Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells
Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
The changes of T lymphocytes and cytokines in ICR mice fed with Fe3O4 magnetic nanoparticles
The effect of magnetic nanoparticles of Fe3O4 on immune function in normal ICR mice
The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells

Readers of this article also read: